Biotech Stock Roundup: Medivation Buyout Rumors Continue, NewLink Plunges On Late-Stage Data
Zacks Investment Research | May 12, 2016 12:07AM ET
Earnings remained in focus this week as well with several small and mid-sized biotech companies reporting results. Meanwhile, Medivation (NASDAQ:MDVN) remains in the news as the acquisition saga continues with more companies rumored to be interested in buying the firm.
Other updates include data presentations as well as label expansions and product approvals.
Recap of the Week’s Most Important Stories
1. With first quarter earnings season drawing to a close, several small and mid-sized biotech companies reported results over the last five trading days. Most of these are companies like Juno (NASDAQ:JUNO) , Kite (NASDAQ:KITE) and Repros which have no approved products in their portfolios and are still in the development stage. In such a scenario, investors are more focused on the pipelines and cash burn.
Kite and Juno are key names in the immuno-oncology space with both looking to bring their lead candidates to market in 2017. While Juno’s JCAR015 is in a registrational phase II study (ROCKET) in adult patients with relapsed/refractory acute lymphoblastic leukemia (Read more: Kite Pharma Posts Narrower-than-Expected Loss in Q1 ).
2. Medivation, which had rejected an unsolicited offer from French drugmaker Sanofi (PA:SASY), continues to be in the news as speculation increases about other companies being interested in acquiring Medivation. The latest rumor is that the company is now interested in selling itself. According to a Reuters article, Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are some of the companies that have signed non-disclosure agreements with Medivation.
3. As part of its ongoing strategic review, ARIAD (NASDAQ:ARIA) has decided to divest its European operations and out-license Iclusig in Europe and a few other countries to Incyte. This deal will allow ARIAD to focus its efforts in the U.S. and it also provides the company with a non-dilutive source of funds. Under this agreement, ARIAD stands to receive up to $275 million including an upfront payment of $140 million plus tiered royalties starting from 32% that could go up to 50%.
4. The FDA expanded the label of AbbVie’s (NYSE:ABBV) cancer treatment, Imbruvica. The label now includes new data from two late-stage studies supporting its expanded use in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
AbbVie and Bristol-Myers also gained EU approval for their blood cancer treatment, Empliciti making it the first and only immunostimulatory antibody approved for multiple myeloma in the EU.
5. NewLink Genetics’ (NASDAQ:NLNK) shares plunged more than 30% on disappointing data from a late-stage study being conducted on its experimental cancer treatment, algenpantucel-L. The study, conducted in patients with resected pancreatic cancer, failed to achieve the primary endpoint. The news comes as a major disappointment considering algenpantucel-L is the most advanced candidate in NewLink’s pipeline. The company is now evaluating the future of its HyperAcute platform.
Get The News You Want
Performance
It was a mixed week for biotech stocks with Gilead recording a decline of 1.99% last week while Vertex gained 3.72% during this period. Meanwhile, Regeneron lost 34.35% over the last six months.
The NASDAQ Biotechnology Index was down 0.78% over the last five trading days (See the last biotech stock roundup here: Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.